Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

LEXINGTON, Mass.--Sep. 10, 2020-- Aldeyra Therapeutics, Inc today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences:

H.C. Wainwright 22nd Annual Global Investment Conference 
Presentation Date: Monday, September 14, 2020
Time: 3:30 p.m. ET

2020 Cantor Global Virtual Healthcare Conference 
Presentation Date: Wednesday, September 16, 2020 (Fireside Chat)
Time: 2:40 p.m. ET

A live webcast of the presentations will be available on the investor relations page of the company’s corporate website at After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.

Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300

Source: Aldeyra Therapeutics, Inc

Related Posts

Subscribe Our Newsletter